300110.SZ
Huaren Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 2.66
+0.38%Oct 30, 2026, 08:27 UTC
Huaren Pharmaceutical said its chairman Chen Zhiguo and five vice presidents plan to acquire company shares worth at least RMB 10 million through a partnership within three months of the plan announcement.
Source:Oct 23, 2026, 08:19 UTC
China's National Medical Products Administration approved a drug registration certificate for Huaren Pharmaceutical (Rizhao)'s potassium phosphate injection, with the approval deemed to satisfy consistency evaluation requirements.
Source:Oct 9, 2026, 08:17 UTC
Qingdao Huarun Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huaren Pharmaceutical, sued Zhongmin Xintou Group Co., Ltd. and Sinopharm Medicinal Materials Co., Ltd. over CNY 321 million, and the Qingdao Intermediate People's Court accepted the case.
Source:Aug 26, 2026, 10:55 UTC
Huaren Pharmaceutical reported its first-half 2026 results: revenue of 605 million yuan, down 3.02% year-on-year; net profit attributable to shareholders of 28.5424 million yuan, down 23.55%; non-recurring net profit of 25.4503 million yuan, down 8.09%. The company plans no cash dividend, no bonus shares, and no capital reserve conversion.
Source:Jul 2, 2026, 08:37 UTC
Huaren Pharmaceutical appointed Zhang Xinzhong as Vice President.